Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GERN Geron	$1.32 -4.3%	$1.43	$1.17 ▼ $5.06	$840.73M	0.64	11.23 million shs	7.54 million shs
MYGN Myriad Genetics	$5.34 -2.9%	$4.90	$3.81 ▼ $29.30	$492.24M	1.91	1.27 million shs	888,124 shs
RGLS Regulus Therapeutics	$8.16	$8.04	$0.83 ▼ $8.35	$564.92M	0.35	998,827 shs	N/A
VSTM Verastem	$4.68 -1.3%	$6.11	$2.10 ▼ $9.10	$257.17M	0.71	1.28 million shs	1.21 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GERN Geron	0.00%	-7.37%	-12.58%	0.00%	-71.97%
MYGN Myriad Genetics	0.00%	-4.64%	+6.16%	-33.91%	-79.79%
RGLS Regulus Therapeutics	0.00%	0.00%	+0.62%	+327.23%	+377.19%
VSTM Verastem	0.00%	-1.68%	-16.43%	-2.09%	+39.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GERN Geron	3.3511 of 5 stars	3.3	2.0	1.3	2.1	1.7	0.6
MYGN Myriad Genetics	4.624 of 5 stars	4.1	4.0	4.1	2.6	1.7	0.6
RGLS Regulus Therapeutics	1.4993 of 5 stars	2.1	5.0	0.0	0.0	3.3	0.0
VSTM Verastem	3.0917 of 5 stars	3.5	5.0	0.0	0.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GERN Geron	2.60	Moderate Buy	$4.61	249.33% Upside
MYGN Myriad Genetics	2.13	Hold	$14.38	169.37% Upside
RGLS Regulus Therapeutics	2.29	Hold	$8.50	4.17% Upside
VSTM Verastem	3.00	Buy	$13.38	185.79% Upside

Current Analyst Ratings Breakdown

Latest VSTM, GERN, RGLS, and MYGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	GERN Geron	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$1.00
6/25/2025	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$16.00 ➝ $12.00
5/21/2025	MYGN Myriad Genetics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$20.00 ➝ $6.00
5/15/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.50 ➝ $9.00
5/9/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
5/8/2025	GERN Geron	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$4.00 ➝ $1.50
5/8/2025	MYGN Myriad Genetics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/7/2025	MYGN Myriad Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$18.00
5/7/2025	MYGN Myriad Genetics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/7/2025	MYGN Myriad Genetics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$19.00 ➝ $10.00
5/7/2025	MYGN Myriad Genetics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $7.00

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GERN Geron	$76.99M	10.92	N/A	N/A	$0.46 per share	2.87
MYGN Myriad Genetics	$837.60M	0.59	$1.00 per share	5.34	$7.70 per share	0.69
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A
VSTM Verastem	$10K	25,716.60	N/A	N/A	($0.65) per share	-7.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GERN Geron	-$174.57M	-$0.21	N/A	N/A	N/A	-119.54%	-47.86%	-26.78%	8/6/2025 (Estimated)
MYGN Myriad Genetics	-$127.30M	-$1.12	N/A	N/A	N/A	-12.20%	-4.95%	-3.39%	8/5/2025 (Estimated)
RGLS Regulus Therapeutics	-$46.36M	-$0.73	N/A	N/A	N/A	N/A	-57.53%	-53.26%	8/6/2025 (Estimated)
VSTM Verastem	-$130.64M	-$3.20	N/A	N/A	N/A	N/A	-2,003.62%	-127.97%	8/6/2025 (Estimated)

Latest VSTM, GERN, RGLS, and MYGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	MYGN Myriad Genetics	-$0.02	N/A	N/A	N/A	$202.30 million	N/A
5/13/2025	Q1 2025	VSTM Verastem	-$0.72	-$0.96	-$0.24	-$0.96	$0.10 million	N/A
5/8/2025	Q1 2025	RGLS Regulus Therapeutics	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A
5/7/2025	Q1 2025	GERN Geron	-$0.04	-$0.03	+$0.01	-$0.03	$49.88 million	$39.60 million
5/6/2025	Q1 2025	MYGN Myriad Genetics	-$0.05	-$0.03	+$0.02	N/A	$200.37 million	$195.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GERN Geron	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GERN Geron	0.44	7.87	6.97
MYGN Myriad Genetics	0.08	1.90	1.71
RGLS Regulus Therapeutics	N/A	16.31	16.31
VSTM Verastem	N/A	3.50	3.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GERN Geron	73.71%
MYGN Myriad Genetics	99.02%
RGLS Regulus Therapeutics	92.38%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
GERN Geron	7.42%
MYGN Myriad Genetics	2.10%
RGLS Regulus Therapeutics	4.35%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GERN Geron	70	636.92 million	589.66 million	Optionable
MYGN Myriad Genetics	2,700	92.18 million	90.24 million	Optionable
RGLS Regulus Therapeutics	30	69.23 million	66.22 million	Optionable
VSTM Verastem	50	54.95 million	53.80 million	Optionable

VSTM, GERN, RGLS, and MYGN Headlines

Recent News About These Companies

Verastem stock rises after LGSOC treatment data published in medical ...

July 13 at 3:00 PM | investing.com

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial ...

July 11 at 6:28 PM | gurufocus.com

Verastem (VSTM) Reports Promising Phase 2 Trial Results in Ovarian Cancer | VSTM Stock News

July 11 at 6:28 PM | gurufocus.com

Verastem stock rises after LGSOC treatment data published in medical journal

July 11 at 5:15 PM | in.investing.com

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

July 11 at 5:07 PM | businesswire.com

Verastem, Inc. (VSTM) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

Verastem KRAS-Mutant Ovarian Cancer Treatment Activity Affirmed in Investigator-Initiated Study

July 8, 2025 | precisionmedicineonline.comP

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 8, 2025 | businesswire.com

BTIG Remains a Buy on Verastem (VSTM)

July 4, 2025 | theglobeandmail.com

Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment

July 4, 2025 | tipranks.com

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

June 30, 2025 | businesswire.com

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from Brokerages

June 28, 2025 | marketbeat.com

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

June 26, 2025 | seekingalpha.com

FY2025 EPS Estimates for Verastem Cut by Cantor Fitzgerald

June 26, 2025 | marketbeat.com

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - Morningstar

June 26, 2025 | morningstar.comM

Royal Bank Of Canada Has Lowered Expectations for Verastem (NASDAQ:VSTM) Stock Price

June 25, 2025 | marketbeat.com

Insider Sell Alert: Daniel Calkins Sells Shares of Verastem Inc (VSTM)

June 24, 2025 | gurufocus.com

Verastem, Inc. (NASDAQ:VSTM) CFO Daniel Calkins Sells 4,110 Shares

June 24, 2025 | marketbeat.com

Dan Paterson Sells 17,808 Shares of Verastem, Inc. (NASDAQ:VSTM) Stock

June 24, 2025 | marketbeat.com

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

June 24, 2025 | businesswire.com

Verastem’s SWOT analysis: biotech stock poised for growth amid challenges

June 15, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM, GERN, RGLS, and MYGN Company Descriptions

Geron NASDAQ:GERN

$1.32 -0.06 (-4.35%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$1.35 +0.03 (+2.58%)

As of 05:25 AM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Myriad Genetics NASDAQ:MYGN

$5.34 -0.16 (-2.91%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$5.34 +0.00 (+0.09%)

As of 07/11/2025 04:04 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Regulus Therapeutics NASDAQ:RGLS

$8.16 0.00 (0.00%)

As of 06/25/2025

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Verastem NASDAQ:VSTM

$4.68 -0.06 (-1.27%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$4.88 +0.20 (+4.17%)

As of 04:47 AM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time